CASI — CASI Pharmaceuticals Share Price
Last trade - 00:00- $34.84m
- $34.98m
- $33.88m
- 42
- 48
- 72
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | 1.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -46.27% | ||
| Return on Equity | -78.44% | ||
| Operating Margin | -79.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.13 | 15.14 | 30.17 | 43.11 | 33.88 | 59.17 | 88.09 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Directors
- Wei-Wu He CHM (55)
- Wei Zhang PRE (62)
- Alexander Zukiwski OTH (63)
- James Huang IND (56)
- Franklin Salisbury IND (65)
- Rajesh Shrotriya IND (77)
- Y. Alexander Wu IND (57)
- Quan Zhou IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 10th, 2023
- Public Since
- August 23rd, 2021
- No. of Shareholders
- 72
- No. of Employees
- 176
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 13,401,375
- Address
- 9620 Medical Center Drive, Suite 300, BEIJING, 100025
- Web
- http://www.casipharmaceuticals.com/
- Phone
- +86 1065618789
- Auditors
- KPMG Huazhen LLP
Upcoming Events for CASI
Similar to CASI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
As of Today at 19:05 UTC, shares in CASI Pharmaceuticals are trading at $2.60. This share price information is delayed by 15 minutes.
Shares in CASI Pharmaceuticals last closed at $2.60 and the price had moved by -11.56% over the past 365 days. In terms of relative price strength the CASI Pharmaceuticals share price has underperformed the S&P500 Index by -28.58% over the past year.
The overall consensus recommendation for CASI Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
CASI Pharmaceuticals does not currently pay a dividend.
CASI Pharmaceuticals does not currently pay a dividend.
CASI Pharmaceuticals does not currently pay a dividend.
To buy shares in CASI Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.60, shares in CASI Pharmaceuticals had a market capitalisation of $34.84m.
Here are the trading details for CASI Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CASI
Based on an overall assessment of its quality, value and momentum CASI Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CASI Pharmaceuticals is $12.00. That is 361.54% above the last closing price of $2.60.
Analysts covering CASI Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CASI Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -15.29%.
As of the last closing price of $2.60, shares in CASI Pharmaceuticals were trading -36.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CASI Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CASI Pharmaceuticals' management team is headed by:
- Wei-Wu He - CHM
- Wei Zhang - PRE
- Alexander Zukiwski - OTH
- James Huang - IND
- Franklin Salisbury - IND
- Rajesh Shrotriya - IND
- Y. Alexander Wu - IND
- Quan Zhou - IND